

## Prevalence of *Trichomonas vaginalis* infections amongst female students' of tertiary institutions in Ogun State, Nigeria

Adetayo Obafemi Solesi <sup>1,\*</sup>, Felix Oluwaseun Diya <sup>1</sup>, Risikat. Ayodele Sowole <sup>2</sup>, Tolulope Grace Daini <sup>2</sup>, Helen Nwakaego Adetoyi <sup>3</sup> and Bernice Adebukunola Odugbemi <sup>4</sup>

<sup>1</sup> Department of Pharmacy Technician Programme, School of Basic Medical Sciences, Ogun State Polytechnic of Health and Allied Sciences, Ilese- Ijebu, Ogun, Nigeria.

<sup>2</sup> Department of Medical Laboratory Technician, School of Basic Medical Sciences, Ogun State Polytechnic of Health and Allied Sciences, Ilese- Ijebu, Ogun, Nigeria.

<sup>3</sup> Department of Environmental Health Science and Diseases control, Ogun State Polytechnic of Health and Allied Sciences, Ilese- Ijebu, Ogun, Nigeria.

<sup>4</sup> Department of Community Health's, Ogun State Polytechnic of Health and Allied Sciences, Ilese- Ijebu, Ogun, Nigeria.

World Journal of Advanced Research and Reviews, 2023, 19(02), 1425–1429

Publication history: Received on 04 July 2023; revised on 26 August 2023; accepted on 29 August 2023

Article DOI: <https://doi.org/10.30574/wjarr.2023.19.2.1638>

### Abstract

*Trichomonas vaginalis* is a parasitic protozoan and the causative agent responsible for vaginal trichomoniasis in women. Trichomoniasis is a sexually transmitted disease with significant public health impacts with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease. TV also affects birth outcomes and is known to be associated with human immune deficiency virus transmission and its acquisition. A cross-sectional study was undertaken; it involves 250 female undergraduate students assessed for *Trichomonas vaginalis* infection. Fifteen milliliters of early morning urine samples were collected with a sterile disposable universal bottle, the trophozoites presence observed within 10 min of samples collection. The urine samples were centrifuged at 25 °C for 13 min at 1,500 rpm. Wet-mount microscopy examination performed using a drop of vortex sediments from the urine samples for their appearances, if bloody or cloudy and also screened for the presence of trophozoites of *Trichomonas vaginalis*. 56 (22.4%) were within the age bracket of 17 – 21 years, 124 (49.9%) were of the age range of 22 – 26 years, 42 (16.8%) were in the age group of 27 – 31 years, and 28 (11.2%) were 31 years and above. The rate of infections was significantly varied by age group, with the highest being in sexually active young women aged between 22–26 years 10 (80.7%) and the lowest in the age group 31 years (7.1%). It concluded that *Trichomonas vaginalis* control should be a public health authorities concern that can manage multiple health inequalities noted in some less privileged towns and villages in Nigeria.

**Keywords:** Cross-sectional; Pelvic inflammatory; *Trichomonas vaginalis*; Trophozoites; Urine samples

### 1. Introduction

*Trichomonas vaginalis* (TV) is a parasitic protozoan and the causative agent responsible for vaginal trichomoniasis in women. Trichomoniasis is a sexually transmitted disease with significant public health impacts with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease. TV also affects birth outcomes and is known to be associated with human immune deficiency virus transmission and its acquisition [1].

*T. vaginalis* infections are not self-limiting and produce non-ulcerative inflammation of the genital epithelium that can progress to necrosis and haemorrhage [2, 3].

\* Corresponding author: Adetayo Obafemi Solesi; Email: [solesi.obafemi@gmail.com](mailto:solesi.obafemi@gmail.com)

*T. vaginalis* is recorded to be more prevalent than other infectious STIs such as: - Chlamydia trachomatis, Neisseria gonorrhoea, and syphilis altogether. The worldwide estimation of *Trichomonas vaginalis* prevalence is 8.1% for women and men, 1.0% [4]. New data on the annual incidence of *Trichomonas vaginalis* estimated to be over 170 million cases globally [5].

WHO, reported that about nine million new cases are recorded in North America yearly [5], and asymptomatic incidences are estimated to be 50%. Burstein et al. also claim that 10% to 50% of *T. vaginalis* infections in women are asymptomatic [6], and the men's rate is probably higher. The profound symptoms known with the clinical diagnosis of *T. vaginalis* include discharge of a yellowish-green frothy, dyspareunia, pruritus, and dysuria [7].

From available data in Nigeria, the prevalence across the country ranged between 0- 51.8%. Most of these studies were on pregnant women in different geo-political zones, and samples were vaginal swabs [8]. This disease occurs during the reproductive years. It is uncommonly for clinical manifestations of this infection reported before menarche or after menopause. The incubation period is 4 to 28 days in about 50% of infected individuals [9].

Trichomoniasis is often asymptomatic in men; more than half of the infected women manifest as vaginitis, cervicitis, urethritis and irritation with frothy malodorous discharge [9]. The impacts outcomes of these infections are especially significant during pregnancy. Indeed, infected pregnant women may develop complications such as preterm birth and low birth weight infants [10].

Mann et al. reported an association between mothers infected with *T. vaginalis* and intellectual disability in their children [11]. One rare case is the transmission of *T. vaginalis* infection onto a newborn child [12], where it causes vaginal and respiratory tract infections in newborns [13, 14].

Some reports from Nigeria indicated that *T. vaginalis* is higher in peri-urban areas than in the villages [15, 16]. As exemplified by Obiajuru and Ogbulie [17], in their study, a high prevalence of *T. vaginalis* was found for participants who lived in urban areas at 57.70%, and those from villages accounted for 39.16%. Also, prevalence was highest amongst the sexually active group aged 11-45 years [18]. This study assessed the prevalence of *Trichomonas vaginalis* amongst female students of tertiary institutions in Ogun State, Nigeria.

---

## 2. Material and methods

A cross-sectional study was undertaken at Ogun State Polytechnic of Health and Allied-Sciences and Tai Solarin University of Education between June 2023 and July 2023. It involves 250 female undergraduate students assessed for *Trichomonas vaginalis* infection. The inclusion criteria were consenting female students who were sexually active.

Ethical approvals obtained from the institution's ethics review committee, and an informed consent-form, was given to each participant.

### 2.1. Study population

Two hundred and fifty female students randomly sampled with consent from two tertiary institutions in Ogun State, i.e, one hundred and twenty-five from each institution.

The urine samples were for analyses from Ogun State Polytechnic of Health and Allied-Sciences and Tai Solarin University of Education students.

### 2.2. Sample collection

Fifteen milliliters of early morning urine samples were collected with a sterile disposable universal bottle as described by Karlowsky et al., [19]. A total of two hundred fifty urine samples were collected using disposable sterile-universal bottles for the samples. At each occasion of sample collection from both institutions, the trophozoites presence observed within 10 min of samples collection.

### 2.3. Urine microscopy examination

The urine samples were centrifuged at 25°C for 13 min at 1,500 rpm. Wet-mount microscopy examination performed using a drop of vortex sediments from the urine samples for their appearances, if bloody or cloudy and also screened for the presence of trophozoites of *Trichomonas vaginalis*.

### 3. Results

The study assessed the prevalence of *Trichomonas vaginalis* as one of the primary agents of urinary tract infections among the female students of both study areas.

#### 3.1. Age distribution of the participants

**Table 1** The participants age distribution

Age distribution	Frequency	Percentage (%)
17 - 21	56	22.4
22 - 26	124	49.9
27 - 31	42	16.8
31+	28	11.2
TOTAL	250	100

The age distribution showed that 56 (22.4%) of the samples collected were within the age bracket of 17 – 21 years, 124 (49.9%) of the subjects were of the age range of 22 – 26 years, 42 (16.8%) participants were in the age group of 27 – 31 years, and 28 (11.2%) of the samples were of the age limit of 31 years and above.

#### 3.2. Urine microscopy analysis

**Table 2** Prevalence of *Trichomonas vaginalis* infection by age groups in the study areas

Age distribution	No. examined	No. infected	Percentage
17 - 21	56	3	5.36
22 - 26	124	10	80.65
27 - 31	42	4	9.5
31+	28	2	7.1
<b>TOTAL</b>	250	19	7.6

Table 2 shows the prevalence of infection with *Trichomonas vaginalis* in age groups and using wet mount diagnostic method. The rate of infections was significantly varied by age group, with the highest being in sexually active young women aged between 22–26 years 10(80.7%) and the lowest in the age group 31 years (7.1%).

### 4. Discussion

*Trichomonas vaginalis* infects the genital tracts; it inhabits the female lower part of the genital tract but the urethra and prostate of the male, replicating by binary fission. *Trichomonas vaginalis*, is only transmitted in human- beings through sexual coitus. The infection may be dormant for some time in women but only about ten days in males [20]. Wet mount microscopy has been used for many decades to diagnose *Trichomonas vaginalis*. The diagnosis is cheap, easy to read and interpret, commonly employed for immediate attention, although not sensitive for men. Its sensitivities range from 50–70% depending on the expertise-of-the reader and read within 10 min of collection [21].

*Trichomonas vaginalis* found to occur more often in the presence of women with a newly identified species of *Mycoplasma* or *Candidatus, Mycoplasma girardi* [22, 23]. Brotman et al. found that *Trichomonas vaginalis* was associated with vaginal microbiota consisting of low proportions of lactobacilli and high proportions of *Mycoplasma*, *Parvimonas*, *Sneathia*, and other anaerobes [24].

In the current study Wet-smear preparation detected infections with *T. vaginalis* (7.6%). And studies conducted in Brazil indicated that the prevalence of *T. vaginalis* infection was 2.6% to 20%<sup>12</sup> in women evaluated in primary healthcare centres at various zones of the nation. Demographic and environmental factors- age, behaviour, educational

level, personal hygiene, sanitation, and diagnostic methods are; factors responsible to various positivity rates in different study areas, [25].

A review by Hezarjaribi et al., they found that the prevalence of trichomoniasis in Iranian women's average age was 24.5 years [26]. And this agreed with our findings with an average age of 24 years. And a study conducted in Maiduguri showed a high rate of 20.8% infection among non-pregnant women [27]. Higher prevalence in young adults may be due to sexual behaviour, limited knowledge about STIs, and possible vaginal microbiota, resulting in physiological changes that may facilitate the establishment and proliferation of the protozoa in young ones[28].

In pregnant women, infection with *T. vaginalis* is generally considered high; in a study carried in Zaria, pregnant women between ages 16 - 25 reported positive for *T. vaginalis* and have a prevalence of 53.57% [29]. In a similar study conducted in Abeokuta, Nigeria, pregnant women between the ages of 20 and 30 had a Prevalence of 21.3%.

---

## 5. Conclusion

*Trichomonas vaginalis* is considered one of the most known sexually transmitted infections (STIs) in Nigeria, and drugs of choice are cheap and readily available. The incidence of this infection varies from one area to another depending on the degree of personal and community patients as well as sexual practices.

It concluded that *Trichomonas vaginalis* control should be a public health authorities concern that can manage multiple health inequalities noted in some less privileged towns and villages in Nigeria.

---

## Compliance with ethical standards

### *Disclosure of conflict of interest*

No conflict of interest is declared by the authors.

### *Statement of ethical approval*

Ethical approvals obtained from the institution's ethics review committee, and an informed consent-form, was given to each participant.

### *Statement of informed consent*

Informed consent was obtained from all individual participants included in the study.

---

## References

- [1] Sorvillo F, Smith L, Kerndt P, Ash L. *Trichomonas vaginalis*, HIV, and AfricanAmericans. *Emerg Infect Dis.* 2001; 7(6):927–32
- [2] Viikki M, Pukkala E, Nieminen P, Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. *Acta Oncologica*, 2000, 39:71–75.
- [3] Wasserheit JN. The interrelationship between human immunodeficiency virus infection and other sexually transmitted diseases. *Sexually Transmitted Diseases*, 1992; 19:61–77.
- [4] World Health Organisation. Global prevalence and incidence of selected curable sexually transmitted infections: overviews and estimates. In: WHO/ HIV/AIDS. Edited by Organization WH. Geneva; 2001
- [5] World Health Organization. An overview of selected curable sexually transmitted diseases, In Global program on AIDS. World Health Organization, Geneva, Switzerland. 1995. 2–27.
- [6] Burstein GR, Zenilman JM. Nongonococcal urethritis a new paradigm. *Clinical Infectious Diseases.* 1999, 28 Suppl. 1; S66–S73.
- [7] Rein, M. F. Clinical manifestations of urogenital trichomoniasis in women, In B. M. Honigberg (ed.), *Trichomonads parasitic in humans.* Springer-Verlag, New York, N.Y. 1990. p. 225–234.
- [8] Ajani TA, Elikwu CJ, Fayemiwo SA, Nwadike V, Tayo B, Anaedobe CG, Shonekan O, Okangba CC, Akanji AM, Omeonu A, Faluyi B, Asini AO, Ajayi EV, Adeyoola OO, Atalabi FB, Nwanane EB. *Trichomonas vaginalis* infection

among asymptomatic undergraduate students in a private university in Ogun state, Nigeria. *Ann ibd. Pg. Med.* 2022. Vol. 20(2); 135-142.

- [9] Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of *Trichomonas vaginalis*. *Clinical Microbiology Reviews*, 1998, 11:300–317.
- [10] Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold A R. *Trichomonas vaginalis* as a cause of perinatal morbidity: a systematic review and meta-analysis. *Sex Trans Dis* 2014; 41: 369–376.
- [11] Mann JR, McDermott S, Barnes TL, Hardin J, Bao H, Zhou L. Trichomoniasis in pregnancy and mental retardation in children. *Ann Epidemiol.* 2009; 19(12):891–9.
- [12] Schwandt A, Williams C, Beigi RH. Perinatal transmission of *Trichomonas vaginalis*: a case report. *J Reprod Med.* 2008; 53(1):59–61.
- [13] Carter JE, Whithaus KC. Neonatal respiratory tract involvement by *Trichomonas vaginalis*: a case report and review of the literature. *Am J Trop Med Hyg.* 2008; 78(1):17–9.
- [14] Temesvari P, Kerekes A, Tege A, Szarka K. Demonstration of *Trichomonas vaginalis* in tracheal aspirates in infants with early respiratory failure. *J Matern Fetal Neonatal Med.* 2002; 11(5):347–9.
- [15] Njoku AJ, Obiajuru IOC, Njoku CJ, Nwokoro EA, Uwaezuoke IC, Anosike IC. Prevalence of *Trichomonas vaginalis* infection among students of tertiary institutions in Imo state, Nigeria. *Niger J Parasitol* 2000; 21: 83-94.
- [16] Obiajuru IOC. Prevalence of *Trichomonas vaginalis* in Owerri, Imo state. M.Sc. Thesis, Imo State University, Owerri 2000.
- [17] Obiajuru IOC and Ogbulie JN. Prevalence of sexually transmitted diseases in three zones of Imo state, Nigeria. *Niger J Microbiol* 2007; 21: 1491-1498.
- [18] Amadi ANC, and Nwagbo AK. *Trichomonas vaginalis* infection among women in Ikwuano, Abia State, Nigeria. *J Appl Sci Env Manag* 2013; 17: 389-393.
- [19] Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of *Escherichia coli* from outpatients are frequently multi-drug: Results from the North American urinary tract infection collaborative alliance-quinolone resistance study. *Antimicrob. Agents Chemother.* (2006); 50(6): 2251-2254.
- [20] Krieger JN. Trichomoniasis in men: old issues and new data. *Sex Transm Dis.* 1995; 22(2):83–96
- [21] Kingston MA, Bansal D, Carlin EM. ‘Shelf life’ of *Trichomonas vaginalis*. *Int J. STD AIDS.* 2003; 14(1):28–9.
- [22] Martin DH, Zozaya M, Lillis RA, Myers L, Nsuami MJ, Ferris MJ. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with *Trichomonas vaginalis* infection. *J Infect Dis.* 2013; 207(12):1922–31
- [23] Fettweis JM, Serrano MG, Huang B, Brooks JP, Glascock AL, Sheth NU, et al. An emerging mycoplasma associated with trichomoniasis, vaginal infection and disease. *PLoS One.* 2014; 9(10)
- [24] Brotman RM, Bradford LL, Conrad M, Gajer P, Ault K, Peralta L, et al. Association between *Trichomonas vaginalis* and vaginal bacterial community composition among reproductive-age women. *Sex Transm Dis.* 2012; 39(10):807–12
- [25] Ambrozio CL, Nagel AS, Jeske S, Bragança GCM, Borsuk S, Villela MM. *Trichomonas vaginalis* prevalence and risk factors for women in Southern Brazil. *Rev Inst Med Trop Sao Paulo.* 2016; 58:61.
- [26] Hezarjaribi HZ, Fakhar M, Shokri A, Teshnizi SH, Sadough A, and Taghavi M. *Trichomonas vaginalis* infection among Iranian general population of women: a systematic review and meta-analysis. *Parasitol Res.* 2015; 114:1291-300.
- [27] Hamafyelto HS, Ikeh IE. Prevalence of *Trichomonas vaginalis* infection among female internally displaced persons in Maiduguri, Nigeria. *Int J Trop Dis Health* 2017; 27: 1-7.
- [28] Rocha DA, Filho RA, Mariño JM, dos Santos CM. “Hidden” sexually transmitted infections among women in primary care health services, Amazonas, Brazil. *Int J STD AIDS.* 2014; 25: 878-86.
- [29] Adeoye GO, Akande AH. Epidemiology of *Trichomonas vaginalis* among women in Lagos metropolis, Nigeria. *Pak J Biol Sci* 2007; 10: 2198-2201.